The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice

Matias Mendeville, Margaretha G. M. Roemer, G. Tjitske Los-de Vries, Martine E. D. Chamuleau, Daphne de Jong, Bauke Ylstra

Research output: Contribution to journalReview articleAcademicpeer-review


Diffuse large B-cell lymphoma (DLBCL) is a widely heterogeneous disease in presentation, treatment response and outcome that results from a broad biological heterogeneity. Various stratification approaches have been proposed over time but failed to sufficiently capture the heterogeneous biology and behavior of the disease in a clinically relevant manner. The most recent DNA-based genomic subtyping studies are a major step forward by offering a level of refinement that could serve as a basis for exploration of personalized and targeted treatment for the years to come. To enable consistent trial designs and allow meaningful comparisons between studies, harmonization of the currently available knowledge into a single genomic classification widely applicable in daily practice is pivotal. In this review, we investigate potential avenues for harmonization of the presently available genomic subtypes of DLBCL inspired by consensus molecular classifications achieved for other malignancies. Finally, suggestions for laboratory techniques and infrastructure required for successful clinical implementation are described.

Original languageEnglish
Article number970063
JournalFrontiers in Oncology
Publication statusPublished - 27 Oct 2022


  • bioinformatics
  • consensus classification
  • diffuse large B-cell lymphoma (DLBCL)
  • genomics
  • next generation sequencing (NGS)

Cite this